Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial

AIM: Sodium glucose co‐transporter‐2 inhibitors (SGLT‐2i) improve cardiorenal outcomes in patients with chronic kidney disease (CKD), with and without type 2 diabetes. The molecular mechanisms underlying these pleiotropic effects remain unclear, yet it is speculated that SGLT‐2i elicit a neurohormon...

Descripción completa

Detalles Bibliográficos
Autores principales: Antlanger, Marlies, Domenig, Oliver, Kaltenecker, Christopher C., Kovarik, Johannes J., Rathkolb, Vincent, Müller, Martin M., Schwaiger, Elisabeth, Hecking, Manfred, Poglitsch, Marko, Säemann, Marcus D., Kopecky, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305250/
https://www.ncbi.nlm.nih.gov/pubmed/34984822
http://dx.doi.org/10.1111/dom.14639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305250/
https://www.ncbi.nlm.nih.gov/pubmed/34984822
http://dx.doi.org/10.1111/dom.14639

Ejemplares similares